Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice

Autor: Alena S. Potapova, Andrey E. Karateev, Elena Yu. Polishchuk, Ekaterina S. Filatova, Vera N. Amirdzhanova, Aleksander M. Lila

Publikováno v: Терапевтический архив, Vol 96, Iss 5, Pp 465-470 (2024)

Background. Clinical guidelines for the treatment of rheumatoid arthritis (RA) recommend reducing the use of glucocorticoids (GCs) due to the high risk of associated complications. Aim. To determine the frequency of GC cancellations and dose reduc

Externí odkaz: https://doaj.org/article/844f2b6d3f7c44808ee780fb6a20ef87

Analysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)

Autor: M. M. Batyushin, M. A. Trubnikova, G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, D. S. Polyakov, S. Sh. Akhmedkhanov, I. G. Bakulin, I. A. Bodrievskaya, I. A. Viktorova, N. G. Vinogradova, A. S. Galyavich, N. P. Garganeeva, N. Yu. Grigorieva, S. B. Erofeeva, M. A. Kercheva, S. G. Kechedzhieva, N. A. Koryagina, S. V. Malchikova, V. A. Nevzorova, S. V. Nedogoda, M. M. Petrova, V. A. Pogrebetskaya, A. P. Rebrov, O. A. Rubanenko, E. A. Safianik, V. V. Skibitsky, E. A. Smirnova, E. A. Starovoitova, R. F. Khamitov, A. I. Chesnikova, T. M. Shabatina, I. I. Shaposhnik, A. R. Vaisberg, A. V. Aparkina, I. N. Barykina, T. I. Batluk, R. A. Bashkinov, A. T. Beybalayeva, Y. A. Belenikina, O. A. Bilevich, Zh. V. Bondareva, A. Yu. Vaskin, T. V. Vlasova, E. V. Galko, T. U. Garifullin, E. D. Gordeychuk, E. V. Grigorieva, I. V. Gubareva, L. K. Danilova, A. I. Dolgushina, E. M. Durygina, D. S. Evdokimov, N. V. Zhdankina, E. I. Zheleznyak, D. S. Zueva, D. S. Ivanova, E. Yu. Ivanchenko, M. V. Kazakovtseva, A. A. Kaznina, N. A. Karoli, D. S. Kaskaeva, Z. F. Kim, M. V. Kozlova, Y. I. Kudrinskaya, A. S. Kuznetsova, E. Yu. Levchenko, I. A. Lukonin, V. O. Lutova, N. A. Magdeeva, E. V. Makarova, N. E. Makarova, M. M. Mamontova, E. S. Melnikov, A. F. Molostvova, T. D. Naborshchikova, I. N. Nikitina, D. P. Novikova, M. V. Novikova, V. I. Pakusina, K. G. Pereverzeva, I. S. Pleshakov, Yu. G. Pokramovich, O. V. Ponomareva, E. A. Popova, N. A. Popova, E. S. Potapova, E. D. Resnyanskaya, M. Yu. Rozhkova, A. O. Rubanenko, M. D. Rudoy, A. S. Salasyuk, L. M. Salimova, V. I. Samokhina, N. Sh. Sanginova, F. I. Sattarova, A. Kh. Safina, D. P. Sirotenko, N. S. Skarzhinskaya, A. V. Skibitsky, E. I. Suchkova, L. E. Tepnadze, A. V. Fendrikova, T. E. Filatova, O. V. Filyushin, O. Yu. Chizhova, T. I. Chudinovskikh, S. S. Yakushin, E. M. Yashina

Publikováno v: Российский кардиологический журнал, Vol 29, Iss 7 (2024)

Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of mark

Externí odkaz: https://doaj.org/article/e6737166623e4811afc3782016a90baa

Evaluation of the impact of a course of therapy with an injectable form of chondroitin sulfate on the duration of remission and quality of life in patients with osteoarthritis

Autor: P. S. Kovalenko, I. S. Dydykina, O. G. Alekseeva, E. L. Shakhramanova, A. S. Potapova, S. I. Glukhova, E. G. Zotkin

Publikováno v: Современная ревматология, Vol 17, Iss 6, Pp 84-91 (2023)

Ensuring a long-lasting effect of the therapy and its safety are important tasks in the treatment of patients with osteoarthritis (OA). Parenteral forms of chondroitin sulfate (CS) used for the background therapy of OA are characterized by proven eff

Externí odkaz: https://doaj.org/article/53ac33443b234510b3b1bc9b3f05bb62

Outcomes of the use of the glycosaminoglycan-peptide complex as monotherapy and in combination with diacerein for the treatment of knee osteoarthritis in real-world practice

Autor: Andrey E. Karateev, Elena Iu. Polishchuk, Alena S. Potapova, Elena V. Matyanova, Ekaterina S. Filatova, Svetlana I. Glukhova, Aleksander M. Lila

Publikováno v: Consilium Medicum, Vol 25, Iss 2, Pp 105-112 (2023)

Background. Slow-acting symptomatic agents (chondroprotectors) in osteoarthritis (OA) combined therapy is a promising approach. Aim. To compare the real-world results of combined therapy with glycosaminoglycan-peptide complex (GPC) and diacerein w

Externí odkaz: https://doaj.org/article/65155bce773f4829a00a52e2dad9789a

Molecular mechanisms of the development of the phenomena of peripheral and central sensitization in rheumatoid arthritis

Autor: A. S. Potapova

Publikováno v: Научно-практическая ревматология, Vol 61, Iss 1, Pp 77-86 (2023)

Modern tactics for the treatment of rheumatoid arthritis is aimed at achieving remission or low activity of the disease, the maximum elimination of the manifestations of the disease and the restoration of physical and social activity of patients. At

Externí odkaz: https://doaj.org/article/795153d7c65a45c3ae7d31969bf56ab2